Status:

COMPLETED

1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus

Lead Sponsor:

Kyunghee University Medical Center

Conditions:

Type 2 Diabetes Mellitus

Eligibility:

All Genders

18-65 years

Brief Summary

The aim of this study was to evaluate the correlation between 1,5-Anhydroglucitol in patients with HbA1C \<7%, and glycemic excursions as assessed by the continuous glucose monitoring system compared ...

Detailed Description

1,5-Anhydroglucitol (AG) is a glucose analogue present in the plasma of healthy subjects. Physiologically, the plasma levels of 1,5-AG are very stable and only a small quantity is excreted in the urin...

Eligibility Criteria

Inclusion

  • HbA1C \< 7%
  • HbA1c modification \<0.5% in the previous 3 months
  • no recent addition of oral hypoglycemic medications or change in insulin dose \>10% previous 3 months

Exclusion

  • pregnancy
  • anemia (Hb \<10.0 g/dL)
  • liver disease (ALT \>2 UNL)
  • hypoalbuminemia (albumin \<3.5 g/dL)
  • serum creatinine \>2 mg/dL
  • acute or chronic renal tubulointerstitial disease
  • severe medical illness

Key Trial Info

Start Date :

February 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 1 2010

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT01161797

Start Date

February 1 2008

End Date

July 1 2010

Last Update

September 30 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kyunghee University Medical Center

Seoul, South Korea, 130-702

1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus | DecenTrialz